Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01189-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846158793736454144 |
|---|---|
| author | Xiaohui Suo Xiaojun Ma Fang Zheng Dongmei Wang Guanchen Bai Liyun Zhao Zhongjing Han Xin Lv Congcong Zhang Ju Wang Kangxin Tuo Zhen Meng Shan Liu Sifeng Gao Jilei Zhang Zongjiu Jiao Jiaojie Song Ling Li Xinxiao Lu Linyu Yuan Kaiqi Liu Xingli Zhao Yingchang Mi |
| author_facet | Xiaohui Suo Xiaojun Ma Fang Zheng Dongmei Wang Guanchen Bai Liyun Zhao Zhongjing Han Xin Lv Congcong Zhang Ju Wang Kangxin Tuo Zhen Meng Shan Liu Sifeng Gao Jilei Zhang Zongjiu Jiao Jiaojie Song Ling Li Xinxiao Lu Linyu Yuan Kaiqi Liu Xingli Zhao Yingchang Mi |
| author_sort | Xiaohui Suo |
| collection | DOAJ |
| format | Article |
| id | doaj-art-1f2c55e6f0394e47b574eee3928bd51f |
| institution | Kabale University |
| issn | 2044-5385 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-1f2c55e6f0394e47b574eee3928bd51f2024-11-24T12:11:35ZengNature Publishing GroupBlood Cancer Journal2044-53852024-11-011411310.1038/s41408-024-01189-2Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemiaXiaohui Suo0Xiaojun Ma1Fang Zheng2Dongmei Wang3Guanchen Bai4Liyun Zhao5Zhongjing Han6Xin Lv7Congcong Zhang8Ju Wang9Kangxin Tuo10Zhen Meng11Shan Liu12Sifeng Gao13Jilei Zhang14Zongjiu Jiao15Jiaojie Song16Ling Li17Xinxiao Lu18Linyu Yuan19Kaiqi Liu20Xingli Zhao21Yingchang Mi22Department of Hematology, Handan Central HospitalDepartment of Hematology, Handan Central HospitalDepartment of Hematology, The Second People’s Hospital of GuiyangDepartment of Hematology, Harrison International Peace HospitalDepartment of Hematology, The Affiliated Tai’an City Central Hospital of Qingdao UniversityDepartment of Hematology, People Hospital of XingTaiDepartment of Hematology, Daqing Oilfied General HospitalDepartment of Hematology, Linyi Central HospitalDepartment of Hematology, Handan Central HospitalDepartment of Hematology, The Second People’s Hospital of GuiyangDepartment of Hematology, The Second People’s Hospital of GuiyangDepartment of Hematology, Harrison International Peace HospitalDepartment of Hematology, Harrison International Peace HospitalDepartment of Hematology, The Affiliated Tai’an City Central Hospital of Qingdao UniversityDepartment of Hematology, The Affiliated Tai’an City Central Hospital of Qingdao UniversityDepartment of Hematology, People Hospital of XingTaiDepartment of Hematology, People Hospital of XingTaiDepartment of Hematology, Inner Mongolia People’s HospitalDepartment of Hematology, Oncology Center, Tianjin People’s HospitalDepartment of Hematology, Oncology Center, Tianjin People’s HospitalState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Hematology, Oncology Center, Tianjin People’s HospitalState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Collegehttps://doi.org/10.1038/s41408-024-01189-2 |
| spellingShingle | Xiaohui Suo Xiaojun Ma Fang Zheng Dongmei Wang Guanchen Bai Liyun Zhao Zhongjing Han Xin Lv Congcong Zhang Ju Wang Kangxin Tuo Zhen Meng Shan Liu Sifeng Gao Jilei Zhang Zongjiu Jiao Jiaojie Song Ling Li Xinxiao Lu Linyu Yuan Kaiqi Liu Xingli Zhao Yingchang Mi Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia Blood Cancer Journal |
| title | Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia |
| title_full | Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia |
| title_fullStr | Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia |
| title_full_unstemmed | Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia |
| title_short | Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia |
| title_sort | venetoclax combined with three day multi frequency decitabine dec3 ven in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia |
| url | https://doi.org/10.1038/s41408-024-01189-2 |
| work_keys_str_mv | AT xiaohuisuo venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT xiaojunma venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT fangzheng venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT dongmeiwang venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT guanchenbai venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT liyunzhao venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT zhongjinghan venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT xinlv venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT congcongzhang venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT juwang venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT kangxintuo venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT zhenmeng venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT shanliu venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT sifenggao venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT jileizhang venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT zongjiujiao venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT jiaojiesong venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT lingli venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT xinxiaolu venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT linyuyuan venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT kaiqiliu venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT xinglizhao venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia AT yingchangmi venetoclaxcombinedwiththreedaymultifrequencydecitabinedec3veninelderorintensivechemotherapyineligiblepatientswithnewlydiagnosedacutemyeloidleukemia |